Case report: Persistent hypogammaglobulinemia in thymoma-associated myasthenia gravis: the impact of rituximab or Good's syndrome?

INTRODUCTION: Rituximab (RTX) showed good efficacy and safety for patients with myasthenia gravis. However, the percentage of peripheral CD20+ B cell may be absent for years after low dose of RTX treatment. Persistent hypogammaglobulinemia and opportunistic infection may occur in patients under trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jingru, Wang, Jianchun, Liu, Ran, Guo, Jing, Yao, Yan, Luo, Jingjing, Hao, Hongjun, Gao, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196171/
https://www.ncbi.nlm.nih.gov/pubmed/37213908
http://dx.doi.org/10.3389/fneur.2023.1152992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196171/
https://www.ncbi.nlm.nih.gov/pubmed/37213908
http://dx.doi.org/10.3389/fneur.2023.1152992

Ejemplares similares